BA
IDXX icon

Bard Associates’s Idexx Laboratories IDXX Stock Holding History

Bard Associates’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.69K Buy
+7
New +$3.93K ﹤0.01% 274

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bard Associates's IDXX Position: Q2 2026 in Review

Bard Associates opened a new position in Idexx Laboratories (IDXX) in Q2 2026: 7 shares worth $3.69K. The stake represents ﹤0.01% of the portfolio and ranks #274 among its holdings.

1,296 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Bard Associates held 7 shares of Idexx Laboratories worth $3.69K as of Q2 2026.
  • Idexx Laboratories was a new Bard Associates position in Q2 2026.
  • Idexx Laboratories made up ﹤0.01% of Bard Associates's portfolio in Q2 2026, its #274 holding.
  • 1,296 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.